BTIG Research Boosts Rapport Therapeutics (NASDAQ:RAPP) Price Target to $75.00

Key Points

• BTIG Research raised Rapport Therapeutics’ price target from $65 to $75 and maintained a “buy” rating, implying 75.73% upside from the prior close.
• Analyst sentiment remains broadly positive, with a consensus “Buy” rating and an average price target of $64.29; Raymond James also set a $75 target, while HC Wainwright raised its target to $66.
• Rapport Therapeutics reported a quarterly loss of $1.19 per share, missing the $1.12 consensus estimate, while the stock opened at $42.68 and was down 3.0%.

Rapport Therapeutics (NASDAQ:RAPP - Get Free Report) had its price target increased by equities research analysts at BTIG Research from $65.00 to $75.00 in a report released on Wednesday, MarketBeat.com reports. The brokerage presently has a "buy" rating on the stock. BTIG Research's price target points to a potential upside of 75.73% from the company's previous close.

Several other research firms have also recently issued reports on RAPP. Raymond James Financial reissued a "strong-buy" rating and issued a $75.00 target price on shares of Rapport Therapeutics in a research report on Monday, August 17th. Leerink Partners started coverage on shares of Rapport Therapeutics in a research report on Wednesday, June 24th. They set an "outperform" rating and a $52.00 price target for the company. HC Wainwright increased their price target on shares of Rapport Therapeutics from $40.00 to $66.00 and gave the stock a "buy" rating in a research note on Wednesday, August 12th. William Blair started coverage on shares of Rapport Therapeutics in a report on Tuesday, July 28th. They issued an "outperform" rating on the stock. Finally, UBS Group reissued a "strong-buy" rating on shares of Rapport Therapeutics in a research note on Monday, August 17th. Two investment analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Rapport Therapeutics has a consensus rating of "Buy" and an average target price of $64.29.

Rapport Therapeutics Trading Down 3.0%

Rapport Therapeutics stock opened at $42.68 on Wednesday. The firm has a market capitalization of $2.05 billion, a P/E ratio of -14.04 and a beta of 1.02. The stock has a fifty day moving average price of $44.90 and a 200 day moving average price of $38.36. Rapport Therapeutics has a 52 week low of $23.75 and a 52 week high of $52.93.

Rapport Therapeutics (NASDAQ:RAPP - Get Free Report) last issued its quarterly earnings results on Wednesday, August 5th. The company reported ($1.19) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.12) by ($0.07). As a group, equities analysts predict that Rapport Therapeutics will post -4.09 EPS for the current year.

Insider Buying and Selling at Rapport Therapeutics

In related news, CEO Abraham Ceesay sold 28,958 shares of Rapport Therapeutics stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $48.01, for a total transaction of $1,390,273.58. Following the transaction, the chief executive officer owned 486,108 shares in the company, valued at approximately $23,338,045.08. The trade was a 5.62% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. In the last quarter, insiders have sold 81,244 shares of company stock worth $3,858,615. Insiders own 12.48% of the company's stock.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in RAPP. Engineers Gate Manager LP purchased a new stake in shares of Rapport Therapeutics in the second quarter worth about $888,000. Wellington Management Group LLP raised its holdings in shares of Rapport Therapeutics by 11.2% during the 2nd quarter. Wellington Management Group LLP now owns 86,988 shares of the company's stock valued at $3,625,000 after buying an additional 8,757 shares during the period. Artia Global Partners LP purchased a new stake in shares of Rapport Therapeutics during the 2nd quarter valued at about $5,772,000. Bank of America Corp DE acquired a new position in Rapport Therapeutics during the 2nd quarter worth approximately $3,170,000. Finally, Jupiter Topco LLC acquired a new position in Rapport Therapeutics during the 2nd quarter worth approximately $574,000.

Rapport Therapeutics Company Profile

Rapport Therapeutics is a clinical-stage biopharmaceutical company focused on developing medicines for disorders of the central nervous system. The company's research centers on receptor-associated proteins, which help regulate neurotransmitter receptors and may provide opportunities to develop more selective therapies than those that target receptors broadly.

Rapport's lead development program, RAP-219, is an orally administered investigational therapy designed to modulate AMPA receptors through their associated proteins.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.